Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32

Journal name:
Nature Genetics
Year published:
Published online

To identify susceptibility loci for non-Hodgkin lymphoma subtypes, we conducted a three-stage genome-wide association study. We identified two variants associated with follicular lymphoma at 6p21.32 (rs10484561, combined P = 1.12 × 10−29 and rs7755224, combined P = 2.00 × 10−19; r2 = 1.0), supporting the idea that major histocompatibility complex genetic variation influences follicular lymphoma susceptibility. We also found confirmatory evidence of a previously reported association between chronic lymphocytic leukemia/small lymphocytic lymphoma and rs735665 (combined P = 4.24 × 10−9).


  1. Skibola, C.F., Curry, J.D. & Nieters, A. Haematologica 92, 960969 (2007).
  2. Skibola, C.F. et al. Nat. Genet. 41, 873875 (2009).
  3. Skibola, C.F. et al. PLoS One 3, e2816 (2008).
  4. Smedby, K.E. et al. J. Natl. Cancer Inst. 97, 199209 (2005).
  5. Cerhan, J.R. et al. Blood 110, 44554463 (2007).
  6. Di Bernardo, M.C. et al. Nat. Genet. 40, 12041210 (2008).
  7. de Bakker, P.I. et al. Nat. Genet. 38, 11661172 (2006).
  8. Klitz, W. et al. Tissue Antigens 62, 296307 (2003).
  9. Al-Tonbary, Y. et al. Hematology 9, 139145 (2004).
  10. Nathalang, O. et al. Eur. J. Immunogenet. 26, 389392 (1999).
  11. Choi, H.B. et al. Int. J. Hematol. 87, 203209 (2008).
  12. Skibola, C.F. et al. Am. J. Epidemiol. 171, 267276 (2010).
  13. Abdou, A.M. et al. Leukemia 24, 10551058 (2010).

Download references

Author information


  1. Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, Berkeley, California, USA.

    • Lucia Conde,
    • Nicholas K Akers,
    • Luz Agana,
    • Jacques Riby,
    • Martyn T Smith &
    • Christine F Skibola
  2. Molecular Microbiology and Biotechnology Department, Tel-Aviv University, Tel-Aviv, Israel.

    • Eran Halperin
  3. International Computer Science Institute, Berkeley, California, USA.

    • Eran Halperin
  4. Integrative Cancer Genomics Division, Translational Genomics Research Institute (TGen), Phoenix, Arizona, USA.

    • Kevin M Brown
  5. Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden.

    • Karin E Smedby
  6. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

    • Nathaniel Rothman,
    • Patricia Hartge,
    • Lindsay M Morton,
    • Sophia S Wang,
    • Mark P Purdue,
    • Qing Lan,
    • Shelia H Zahm,
    • Neil E Caporaso,
    • Lynn R Goldin &
    • Stephen Chanock
  7. Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.

    • Alexandra Nieters,
    • Nikolaus Becker &
    • Katja Butterbach
  8. Molecular Epidemiology, Centre of Chronic Immunodeficiency, University of Freiburg Medical Centre, Freiburg, Germany.

    • Alexandra Nieters
  9. Mayo Clinic College of Medicine, Rochester, Minnesota, USA.

    • Susan L Slager,
    • Sara J Achenbach,
    • Timothy G Call,
    • James R Cerhan,
    • Julie M Cunningham,
    • Curtis A Hanson,
    • Neil E Kay,
    • Jose F Leis,
    • Kari G Rabe &
    • Celine M Vachon
  10. British Columbia Cancer Research Center, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

    • Angela Brooks-Wilson &
    • John J Spinelli
  11. Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Vancouver, British Columbia, Canada.

    • Angela Brooks-Wilson
  12. Human Genetics, Genome Institute of Singapore, A*STAR, Singapore.

    • Jianjun Liu &
    • Hui-Qi Low
  13. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

    • Hans-Olov Adami,
    • Hatef Darabi &
    • Keith Humphreys
  14. Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA.

    • Hans-Olov Adami
  15. Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.

    • Henrik Hjalgrim &
    • Mads Melbye
  16. Cancer Prevention Institute of California (formerly the Northern California Cancer Center), Fremont, California, USA.

    • Ellen T Chang
  17. Division of Epidemiology, Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California, USA.

    • Ellen T Chang
  18. Department of Oncology and Pathology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.

    • Bengt Glimelius
  19. Department of Oncology, Radiology and Clinical Immunology, Akademiska Hospital, Uppsala University, Uppsala, Sweden.

    • Bengt Glimelius
  20. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

    • Wendy Cozen
  21. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

    • Scott Davis
  22. Department of Family Medicine and Public Health Sciences, Wayne State University, Detroit, Michigan, USA.

    • Maryjean Schenk
  23. Division of Etiology, Beckman Research Institute and the City of Hope, Duarte, California, USA.

    • Sophia S Wang
  24. Sydney School of Public Health, The University of Sydney, Sydney, Australia.

    • Bruce Armstrong &
    • Anne Kricker
  25. Department of Haematology, St. Vincent's Hospital, Sydney, Australia.

    • Sam Milliken
  26. University of New South Wales Cancer Research Center, Prince of Wales Clinical School, Sydney, Australia.

    • Claire M Vajdic
  27. International Prevention Research Institute, Lyon, France.

    • Peter Boyle &
    • Paolo Boffetta
  28. School of Public Health, Yale University, New Haven, Connecticut, USA.

    • Yawei Zhang &
    • Tongzhang Zheng
  29. Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Catalan Institute of Oncology, Barcelona, Spain.

    • Yolanda Benavente &
    • Silvia de Sanjosé
  30. The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York, USA.

    • Paolo Boffetta
  31. International Agency for Research on Cancer, Lyon, France.

    • Paul Brennan
  32. Department of Public Health, Occupational Health Section, University of Cagliari, Cagliari, Italy.

    • Pierluigi Cocco
  33. Masaryk Memorial Cancer Institute, Brno, Czech Republic.

    • Lenka Foretova
  34. Registry of Hematological Malignancies, EA4184, University of Burgundy, University Hospital of Dijon, Dijon, France.

    • Marc Maynadié
  35. School of Public Health and Population Science, University College Dublin, Dublin, Ireland.

    • Anthony Staines
  36. School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.

    • John J Spinelli
  37. University of Utah School of Medicine, Department of Biomedical Informatics, Salt Lake City, Utah, USA.

    • Nicola J Camp &
    • Martha Glenn
  38. Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.

    • Mark C Lanasa &
    • J Brice Weinberg
  39. Division of Cell and Gene Therapies, Office of Cellular, Tissues and Gene Therapies, US Food and Drug Administration, US National Institutes of Health, Bethesda, Maryland, USA.

    • Gerald E Marti
  40. Moores Cancer Center, University of California, San Diego, La Jolla, California, USA.

    • Laura Z Rassenti
  41. Prevention and Etiology Research Program, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.

    • Logan G Spector
  42. Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.

    • Sara S Strom
  43. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.

    • Elizabeth A Holly &
    • Paige M Bracci


Design and interpretation of overall study: C.F.S., E.H., K.M.B., M.T.S., P.M.B. Primary data analysis: L.C., E.H. Drafting of manuscript: L.C., C.F.S. Critical revision of manuscript: E.H., K.M.B., A.B.-W., B.A., C.M. Vajdic., S.C., M.T.S., P.M.B. Study design, genotyping and statistical analysis of individual studies: SF1, SF1B and SF2: L.C., E.H., J.R., N.K.A., L.A., E.A.H., M.T.S., P.M.B., C.F.S. SCALE: K.E.S., J.L., H.-O.A., H.D., H.H., H.-Q.L., K.H., M. Melbye, E.T.C., B.G. NCI-SEER: N.R., W.C., S.D., P.H., L.M.M., M.S., S.S.W., S.C., J.R.C. NSW: B.A., A.K., S.M., M.P.P., C.M. Vajdic. Yale: P. Boyle, Q.L., S.H.Z., Y.Z., T.Z. EpiLymph: A.N., N.B., Y.B., P. Boffetta, P. Brennan, K.B., P.C., L.F., M. Maynadié,, A.S. BC: A.B.-W., J.J.S. Mayo-GEC: S.L.S., S.J.A., T.G.C., M.G., N.J.C., N.E.C., J.R.C., J.M.C., L.R.G., C.A.H., N.E.K., M.C.L., J.F.L., G.E.M., K.G.R., L.Z.R., L.G.S., S.S.S., C.M. Vachon, J.B.W. All authors contributed to the final manuscript and approved its content.

Competing financial interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to:

Author details

Supplementary information

PDF files

  1. Supplementary Text and Figures (1.4M)

    Supplementary Tables 1–11, Supplementary Figures 1–5 and Supplementary Methods

Additional data